Literature DB >> 29902450

Circular RNA circ-CBFB promotes proliferation and inhibits apoptosis in chronic lymphocytic leukemia through regulating miR-607/FZD3/Wnt/β-catenin pathway.

Liang Xia1, Linlin Wu2, Jing Bao1, Qingsheng Li1, Xiaowen Chen1, Hailong Xia1, Ruixiang Xia3.   

Abstract

Circular RNA (circRNA) belongs to the non-coding RNA family and is involved in various human cancers, such as lung cancer and colorectal cancer. Nevertheless, whether circRNA expression is related to chronic lymphocytic leukemia (CLL) progression remains largely unclear. In our study, we investigated the role of circ-CBFB in CLL. We found that circ-CBFB was markedly overexpressed in CLL cells compared to normal controls. Furthermore, we found that circ-CBFB could serve as a diagnostic and prognostic biomarker for CLL patients. We also explored the physiological function of circ-CBFB. We found that circ-CBFB knockdown significantly suppressed CLL cell proliferation, arrested cell cycle progression, and induced cellular apoptosis. In terms of its mechanism, we identified circ-CBFB as a sponge of miR-607, which targeted FZD3. By inhibiting miR-607 availability, circ-CBFB promoted FZD3 expression, leading to the activation of the Wnt/β-catenin pathway and consequent CLL progression. Taken together, our findings revealed that the circ-CBFB/miR-607/FZD3/Wnt/β-catenin regulatory signaling cascade contributes to CLL progression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Chronic lymphocytic leukemia; Circ-CBFB; Proliferation

Mesh:

Substances:

Year:  2018        PMID: 29902450     DOI: 10.1016/j.bbrc.2018.06.045

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  41 in total

Review 1.  Roles of circRNAs in hematological malignancies.

Authors:  Fahua Deng; Chengsi Zhang; Tingting Lu; Ezhong Joshua Liao; Hai Huang; Sixi Wei
Journal:  Biomark Res       Date:  2022-07-15

2.  Competing endogenous RNA networks related to prognosis in chronic lymphocytic leukemia: comprehensive analyses and construction of a novel risk score model.

Authors:  Xin Zhang; Yang Han; Xinting Hu; Hua Wang; Zheng Tian; Ya Zhang; Xin Wang
Journal:  Biomark Res       Date:  2022-10-21

Review 3.  Tip of the iceberg: roles of circRNAs in hematological malignancies.

Authors:  Shan-Shan Guo; Bi-Xia Li; Duo-Bing Zou; Shu-Jun Yang; Li-Xia Sheng; Gui-Fang Ouyang; Qi-Tian Mu; He Huang
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

4.  IncRNA ZFAS1 contributes to the radioresistance of nasopharyngeal carcinoma cells by sponging hsa-miR-7-5p to upregulate ENO2.

Authors:  Jiaojiao Peng; Feng Liu; Hong Zheng; Qi Wu; Shixi Liu
Journal:  Cell Cycle       Date:  2020-12-20       Impact factor: 4.534

5.  CircCBFB is a mediator of hepatocellular carcinoma cell autophagy and proliferation through miR-424-5p/ATG14 axis.

Authors:  Zidan Zhao; Junjian He; Chao Feng
Journal:  Immunol Res       Date:  2022-01-23       Impact factor: 2.829

Review 6.  Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers.

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

7.  CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value.

Authors:  Bo Xu; Tieyi Yang; Zhi Wang; Yan Zhang; Shuyi Liu; Mingquan Shen
Journal:  Cancer Manag Res       Date:  2018-10-23       Impact factor: 3.989

Review 8.  Roles of CircRNAs in Autoimmune Diseases.

Authors:  Xin Xia; Xinyi Tang; Shengjun Wang
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

9.  Expression of circular RNAs in gynecological tumors: A systematic review.

Authors:  Kangsheng Liu; Qin Zhang; Feng Pan; Xiang Dong Wang; Hu Wenjing; Hua Tong
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 10.  Role of circular RNA in hematological malignancies.

Authors:  Mei Mei; Yingjun Wang; Zhaoming Li; Mingzhi Zhang
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.